Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nottingham
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Nottingham, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca18 Hoffmann-La Roche15 Merck Sharp & Dohme LLC12 AbbVie11 Eli Lilly and Company6
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Nottingham

205 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
AbbVie
Phase 3
520
Plymouth, Edinburgh, London, Portsmouth, Airdrie, Nottingham
2026-11-30
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
London, Sutton, Birmingham, Cambridge, Glasgow, Liverpool, Manchester, Nottingham
2026-09-29
Recruiting
Agomab Spain S.L.U.
Phase 1
8
Nottingham
2026-09-09
Recruiting
Novartis Pharmaceuticals
Phase 1
30
Nottingham
2026-09-02
Recruiting
Cochlear
Not applicable
20
London, Nottingham, Sheffield
2026-07-24
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
150
Bristol, Liverpool, London, Nottingham
2026-06-02
Recruiting
Alfasigma S.p.A.
Phase 3
65
Bristol, Leicester, Nottingham
2026-05-21
Recruiting
Incyte Corporation
Phase 1
218
London, Nottingham, Oxford
2026-05-11
Recruiting
AstraZeneca
Phase 3
420
Edinburgh, Hampshire, Leeds, London, Manchester, Nottingham, Oxford, Sutton
2026-05-05
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Antrim, Birmingham, Bristol, Cardiff, Exeter, London, Nottingham, Oxford
2026-05
Recruiting
Tessera Therapeutics, Inc.
Phase 1/2
72
London, Nottingham
2026-04-21
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
London, Nottingham, Plymouth, Southampton
2026-04-17
Recruiting
PS-002 for the Treatment of IgA Nephropathy in Adults
NCT07182227Immunoglobulin A (IgA) Nephropathy
Purespring Therapeutics Limited
Phase 1/2
32
Manchester, Leicester, Nottingham, Bristol, Cardiff, Edinburgh, London
2026-03-30
Active, closed
Boehringer Ingelheim
Phase 1
80
Nottingham
2026-03-11
Recruiting
Abivax S.A.
Phase 1
44
Nottingham
2026-03-03
Recruiting
Eli Lilly and Company
Phase 3
1,000
Edinburgh, Exeter, Glasgow, London, Nottingham, Oxford, Penzance, Rotherham
2026-02-09
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Canterbury, Cardiff, Dundee, London, Nottingham, Portsmouth, Sutton
2026-02-04
Recruiting
CSL Behring
Phase 2
84
Glasgow, Belfast, Bristol, Liverpool, London, Norwich, Nottingham, Oxford
2026-01-22
Recruiting
Generate Biomedicines
Phase 3
786
High Wycombe, Ashburton, Bristol, London, Romford, Rotherham, Thetford, Nottingham
2026-01-20
Recruiting
ConvaTec Inc.
Not applicable
87
Bollington, Knutsford, Dorchester, Swaffham, Ashington, Nottingham
2026-01-12
Active, closed
Taiho Oncology, Inc.
Phase 3
360
Manchester, Nottingham, Torquay, Cardiff
2025-12-22
Active, closed
Kailera
Phase 3
2,530
Soham, Torpoint, Hull, Stevenage, Leicester, Nottingham, Newcastle upon Tyne, Bradford
2025-12-18
Recruiting
Draig Therapeutics Ltd
Phase 2
300
Chester, Eastbourne, Glasgow, London, Nottingham, Oxford
2025-12-16
Recruiting
Société des Produits Nestlé (SPN)
Not applicable
50
Nottingham, Worcester
2025-12-10
Recruiting
ALX Oncology Inc.
Phase 2
120
London, Cardiff, Nottingham
2025-12-10
Recruiting
Boehringer Ingelheim
Phase 3
120
Birmingham, Bristol, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton
2025-12-09
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Cambridge, London, Chelsea, Sutton, Stoke-on-Trent, Nottingham, Wolverhampton
2025-11-30
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
Cambridge, Cardiff, Edinburgh, Liverpool, London, Nottingham, Oxford
2025-11-25
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Brighton, Romford, Coventry, Glasgow, Leeds, London, Nottingham
2025-11-11
Recruiting
AstraZeneca
Phase 3
420
Glasgow, Scotland, London, Manchester, Newcastle upon Tyne, Nottingham
2025-11-11
Recruiting
Daiichi Sankyo
Phase 3
686
Eastbourne, London, Londonderry, Nottingham
2025-10-24
Recruiting
WSAUD A/S
Not applicable
70
Nottingham, Sunderland, Wigan
2025-09-30
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
DrugEmpasiprubart
argenx
Phase 3
160
Nottingham, London, Salford
2025-09-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Truro, London, Belfast, Manchester, Nottingham
2025-09-11
Recruiting
Relay Therapeutics, Inc.
Phase 3
540
Bath, Cardiff, London, Manchester, Nottingham, Swindon, Truro
2025-08-26
Active, closed
Vir Biotechnology, Inc.
Phase 2
100
London, Manchester, Nottingham
2025-08-05
Active, closed
Vir Biotechnology, Inc.
Phase 3
150
London, Manchester, Nottingham
2025-07-30
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Cambridge, Guildford, Hampstead, London, Maidstone, Manchester, Nottingham
2025-07-17
Recruiting
Takeda
Phase 3
347
London, Birmingham, Canterbury, Hull, Leicester, Nottingham, Preston, Sheffield
2025-07-15
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
London, Dundee, Huddersfield, Colchester, Orpington, Nottingham, Blackpool, Leicester
2025-06-30
Recruiting
Bristol-Myers Squibb
Phase 1
236
Nottingham
2025-06-27
Active, closed
Incyte Corporation
Phase 3
159
Glasgow, London, Metropolitan Borough of Wirral, Nottingham, Sheffield, Walsall
2025-06-17
Recruiting
SecuraBio
Phase 3
124
Sutton, Glasgow, Leicester, London, Manchester, Nottingham, Oxford
2025-05-19
Recruiting
Société des Produits Nestlé (SPN)
Not applicable
25
Nottingham
2025-04-14
Recruiting
AstraZeneca
Phase 3
400
Belfast, Birmingham, Bradford, Bristol, Chorley, Leeds, Liverpool, Nottingham
2025-03-28
Recruiting
AbbVie
Observational
700
Milton Keynes, Truro, Cheltenham, Portsmouth, Airdrie, Nottingham, Manchester, Newcastle upon Tyne
2025-03-28
Active, closed
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
NCT06673056Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
DrugN-Acetyl-L-Leucine
IntraBio Inc
Phase 3
60
Cambridge, Nottingham
2025-03-18
Recruiting
Hoffmann-La Roche
Phase 3
600
Cambridge, Harrow, Liverpool, London, Newcastle upon Tyne, North Shields, Nottingham
2025-03-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Truro, London, Nottingham, Taunton, Birmingham, Cardiff, Leeds
2025-03-16
Active, closed
Vir Biotechnology, Inc.
Phase 3
124
London, Manchester, Nottingham
2025-03-12
Recruiting
UCB Biopharma SRL
Phase 3
40
Bristol, Manchester, Nottingham, Stoke-on-Trent
2025-03-11
Recruiting
BioNTech SE
Phase 3
621
Manchester, Chelsea, Sutton, Huddersfield, Newcastle upon Tyne, Nottingham, Oxford, Dundee
2025-02-03
Recruiting
Incyte Corporation
Phase 3
240
Bristol, Glasgow, Leeds, London, Manchester, Nottingham, Plymouth
2025-01-21
Active, closed
Hoffmann-La Roche
Phase 1
75
Nottingham, Swansea
2024-12-17
Active, closed
Kumquat Biosciences Inc.
Phase 1
13
London, Nottingham
2024-12-09
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
London, Manchester, Norwich, Nottingham, Plymouth
2024-11-27
Active, closed
AbbVie
Observational
1,314
Hull, Edinburgh, London, Nottingham, Stoke-on-Trent, Leeds, Swindon, Worcester
2024-11-26
Active, closed
Genmab
Phase 3
191
Glasgow, London, Manchester, Nottingham, Plymouth
2024-11-25
Active, closed
Sanofi
Phase 2
556
Ruislip, Corby, Nottingham, Oxford, Barnsley, Bradford, London
2024-11-07
Recruiting
Dermal Laboratories Ltd
Not applicable
65
Nottingham
2024-10-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Bristol, London, Nottingham, Leeds, Leicester, Manchester, Metropolitan Borough of Wirral, Portsmouth
2024-10-21
Active, closed
Ipsen
Observational
424
Aberdeen, Belfast, Birmingham, Bradford, Hull, London, Newcastle, Nottingham
2024-10-14
Recruiting
TrueBlue Clinical Study - Investigating the Use of a Mobile Phone App TrueBlue for Monitoring Depression and Anxiety
NCT06364488Depression, Depression, Postpartum, Anxiety in Pregnancy, Anxiety
BlueSkeye AI
Not applicable
125
Nottingham
2024-10-01
Active, closed
Nocion Therapeutics
Phase 2
455
Belfast, Bristol, Cottingham, London, Wythenshawe, Nottingham, North Shields
2024-09-24
Active, closed
Hoffmann-La Roche
Phase 3
338
Cambridge, Cottingham, Glasgow, Leeds, London, Nottingham, Sutton, Torquay
2024-09-23
Active, closed
Amgen
Phase 3
315
Nottingham
2024-09-09
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
London, Nottingham, Birmingham, Newcastle upon Tyne, Whitechapel
2024-09-04
Active, closed
Celgene
Phase 2
95
Southampton, Canterbury, Edinburgh, Nottingham
2024-08-30
Active, closed
Genmab
Phase 3
379
Truro, Airdrie, Nottingham, Newcastle upon Tyne
2024-08-13
Recruiting
AstraZeneca
Phase 3
1,018
London, Newcastle upon Tyne, Norwich, Nottingham, Plymouth, Southampton
2024-08-07
Recruiting
AbbVie
Phase 3
170
Nottingham
2024-08-05
Recruiting
Boehringer Ingelheim
Phase 1/2
768
Cardiff, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Sutton
2024-06-28
Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
London, Nottingham, Sheffield
2024-06-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Londonderry, Torquay, London, Nottingham
2024-06-10
Active, closed
AbbVie
Phase 3
421
Cambridge, Edinburgh, London, Nottingham, Leeds, Manchester
2024-05-19
Active, closed
Pfizer
Observational
360
Glasgow, Nottingham, Oxford, Edinburgh, Crumpsall, Kent, London, Newport
2024-05-08
Recruiting
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
NCT06164730Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
DrugVERVE-102
Verve Therapeutics, Inc.
Phase 1
85
Birmingham, Cambridge, Edinburgh, London, Manchester, Nottingham
2024-04-30
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Exeter, Kent, London, Swansea, Nottingham, Oxford, Cardiff, Bristol
2024-04-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Londonderry, Truro, London, Blackpool, Nottingham
2024-04-14
Recruiting
GlaxoSmithKline
Phase 3
864
Edinburgh, Gloucester, London, Nottingham, Sutton, Wolverhampton
2024-03-21
By invitation
Sarepta Therapeutics, Inc.
Phase 1/2
78
London, Nottingham, Southampton
2024-03-04
Active, closed
Sanofi
Phase 3
464
Bristol, Plymouth, London, Portsmouth, Leeds, Nottingham, Liverpool
2024-02-29
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Cambridge, Coventry, London, Nottingham
2024-02-26
Active, closed
ReCode Therapeutics
Phase 2
128
Birmingham, Cambridge, Leeds, London, Nottingham, Southampton
2024-02-01
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Blackpool, Cardiff, Dundee, Leeds, London, Nottingham, Plymouth, Portsmouth
2024-01-22
Active, closed
DualityBio Inc.
Phase 3
541
Truro, London, Southampton, Manchester, Maidstone, Middlesex, Nottingham, Bath
2024-01-18
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
100
Cardiff, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton
2024-01-16
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsErbitux·Cetuximab
AVEO Pharmaceuticals, Inc.
Phase 3
410
Aberdeen, London, Nottingham, Sutton, Torquay
2024-01-11
Active, closed
TransThera Sciences (Nanjing), Inc.
Phase 3
200
London, Manchester, Nottingham
2023-12-20
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
London, Nottingham, Torquay
2023-12-18
Recruiting
Biogen
Observational
20
London, Salford, Southampton, Nottingham, Oswestry, Sheffield, Newcastle upon Tyne, Birmingham
2023-12-15
Active, closed
AstraZeneca
Phase 2
108
Birmingham, Gloucester, London, Norwich, Nottingham, Plymouth
2023-12-13
Active, closed
argenx
Observational
413
Bristol, Fulwood, Glasgow, Nottingham, Oxford, Salford, Sheffield, Taunton
2023-11-29
Active, closed
Incyte Corporation
Phase 3
450
Ipswich, Leicester, London, Nottingham, Walsall
2023-11-27
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Leicester, Nottingham, Taunton, Bodelwyddan, London
2023-11-16
Recruiting
Amgen
Phase 3
750
Birmingham, Inverness, London, Northwood, Nottingham, Sutton, Torquay, Truro
2023-11-16
Recruiting
Takeda
Phase 3
80
London, Manchester, Nottingham, Birmingham
2023-11-13
Active, closed
Ipsen
Observational
1,057
Leicester, Liverpool, London, Middlesbrough, Nottingham
2023-11-01
Recruiting
LeonaBio
Phase 3
600
Cardiff, Harlow, Leeds, London, Manchester, Milton Keynes, Nottingham, Stockton-on-Tees
2023-10-31
Recruiting
Hoffmann-La Roche
Phase 3
230
Belfast, Blackpool, Colchester, Essex, Northwood, Nottingham, Oxford
2023-09-08
Recruiting
AstraZeneca
Phase 3
231
Birmingham, Bradford, Bristol, Glasgow, Leicester, London, Nottingham, Stoke-on-Trent
2023-08-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
735
Nottingham, London-Camden
2023-08-08
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Barnet, London, Manchester, Nottingham
2023-07-31
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Bristol, Brighton, Salford, Leicester, London, Nottingham
2023-07-06
Active, closed
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT05926765Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
MeiraGTx, LLC
Phase 2
290
Cambridge, Cardiff, Dundee, Glasgow, Leeds, London, Nottingham, York
2023-06-13
Active, closed
Apellis Pharmaceuticals, Inc.
Phase 3
100
London, Manchester, Nottingham
2023-05-29
Active, closed
AstraZeneca
Phase 3
37
Nottingham
2023-05-08
Active, closed
Gilead Sciences
Phase 3
654
London, Manchester, Nottingham
2023-05-08
Active, closed
Umecrine Cognition AB
Phase 1/2
202
Birmingham, Glasgow, London, Newcastle, Nottingham, Oxford, Portsmouth, Wolverhampton
2023-04-14
Active, closed
AstraZeneca
Phase 2
188
London, Nottingham
2023-03-06
Recruiting
Takeda
Phase 3
160
Cambridge, Edinburgh, London, Nottingham, Plymouth
2023-03-06
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Birmingham, London, Nottingham
2023-02-03
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Nottingham, Cannock, London, Manchester, Newcastle upon Tyne
2023-01-02
Active, closed
Celcuity Inc
Phase 3
701
Bath, Cardiff, London, Manchester, Nottingham, Sutton
2022-12-08
Recruiting
Janssen Research & Development, LLC
Phase 2
520
Cheltenham, Devon, Edinburgh, Leicester, London, Nottingham, Portsmouth
2022-11-11
Recruiting
Bayer
Phase 3
100
London, Manchester, Nottingham, Glasgow
2022-11-08
Active, closed
Hoffmann-La Roche
Phase 1
121
Glasgow, London, Nottingham, Oxford
2022-10-26
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Blackpool, Dundee, London, Newcastle upon Tyne, Nottingham, Plymouth, Sutton, Wolverhampton
2022-10-13
Recruiting
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
NCT05302934Degenerative Osteoarthritis, Rheumatoid Arthritis, Posttraumatic Arthropathy, Chronic Instability of Knee
Aesculap AG
Observational
600
Nottingham
2022-09-28
Active, closed
AbbVie
Phase 2
125
London, Northwood, Nottingham, Taunton, Sutton, Manchester
2022-09-28
Recruiting
Xiros Ltd
Observational
58
Canterbury, London, Nottingham, Reading
2022-09-26
Active, closed
Sanofi
Phase 2/3
1,856
Bristol, London, Glasgow, Portsmouth, Leicester, Nottingham, Liverpool
2022-08-22
Active, closed
AbbVie
Observational
785
Exeter, Hull, Basingstoke, Bury, Kettering, Nottingham, Oxford, Belfast
2022-08-15
Active, closed
Genentech, Inc.
Phase 3
373
Dorchester, London, Manchester, Nottingham
2022-08-03
Active, closed
Bausch Health Americas, Inc.
Phase 3
466
Dundee, Hull, Liverpool, Nottingham, Plymouth
2022-08-03
Recruiting
Step Pharma, SAS
Phase 1/2
180
Leicester, London, Manchester, Nottingham, Oxford, Plymouth, Sutton
2022-08-03
Active, closed
Gilead Sciences
Phase 3
443
Edinburgh, Glasgow, Leeds, London, Nottingham
2022-07-25
Active, closed
Hoffmann-La Roche
Phase 3
922
Bath, Blackpool, Cleveland, London, Maidstone, Nottingham, Preston, Rhyl
2022-07-18
Active, closed
Celgene
Phase 3
939
Nottingham, Belfast Northern Ireland, Birmingham, Canterbury Kent, Lancashire Blackpool, London, Oxford, Portsmouth
2022-06-23
Recruiting
Priothera SAS
Phase 3
366
Birmingham, Cardiff, Glasgow, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford
2022-06-16
Active, closed
AstraZeneca
Phase 3
644
Bristol, Cardiff, Edinburgh, London, Northampton, Nottingham, Warwick
2022-05-16
Active, closed
Hoffmann-La Roche
Phase 3
1,300
Nottingham, Exeter, Liverpool, London, Newcastle, Swansea
2022-05-03
Recruiting
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
NCT05329532Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck
DrugPembrolizumab
Scancell Ltd
Phase 1/2
168
Brighton, Cardiff, Edinburgh, Guildford, London, Manchester, Nottingham, Preston
2022-04-07
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
466
Basildon, Bellshill, Birmingham, Carshalton, Leicester, London, Manchester, Nottingham
2022-03-30
Active, closed
Bayer
Phase 3
219
London, Manchester, Nottingham, Glasgow
2022-03-28
Recruiting
AbbVie
Phase 3
768
London, Nottingham, Birmingham, Manchester
2022-03-25
Recruiting
Amgen
Phase 3
60
Birmingham, Liverpool, Nottingham, Oxford
2022-03-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
London, Nottingham, Glasgow, Manchester, Swansea
2022-03-15
Active, closed
Daiichi Sankyo
Phase 3
740
Birmingham, Nottingham
2022-03-04
Active, closed
AstraZeneca
Phase 3
390
Birmingham, Blackpool, London, Nottingham, Wythenshawe
2022-02-21
Active, closed
Eli Lilly and Company
Phase 3
152
London, Nottingham, Wolverhampton
2021-12-20
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Edinburgh, Glasgow, Guildford, London, Newcastle upon Tyne, Nottingham
2021-12-10
Recruiting
Janssen Pharmaceutica N.V., Belgium
Observational
300
Bristol, London, Maidstone, Nottingham, Surrey
2021-11-18
Active, closed
Hoffmann-La Roche
Phase 3
478
Cornwall, London, Nottingham, Torquay
2021-10-27
Active, closed
AstraZeneca
Phase 3
732
Blackpool, Bristol, Cardiff, Colchester, Edinburgh, London, Manchester, Nottingham
2021-10-18
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
London, Nottingham, Oxford
2021-10-06
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
333
Southampton, Birmingham, Belfast, London, Newcastle upon Tyne, Nottingham
2021-09-22
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
689
Edinburgh, Leeds, Newcastle upon Tyne, Newmarket, Norwich, Nottingham, Plymouth
2021-09-13
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Leicester, London, Nottingham, Preston
2021-08-27
Active, closed
Inventiva Pharma
Phase 3
1,000
London, Manchester, Newcastle upon Tyne, Nottingham, Preston, Sheffield, Surrey Quays, Glasgow
2021-08-19
Recruiting
Bristol-Myers Squibb
Phase 3
102
Manchester, Nottingham
2021-07-21
Active, closed
AstraZeneca
Phase 3
315
Blackpool, Cambridge, London, Manchester, Newport, Nottingham, Portsmouth, Reading
2021-06-30
Active, closed
Daiichi Sankyo
Phase 2
155
London, Nottingham, Oxford
2021-06-03
Active, closed
Incyte Corporation
Phase 3
899
Aberdeen, Bath, Birmingham, Bristol, London, Nottingham, Sutton, Wolverhampton
2021-05-11
Recruiting
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis
AgNovos Healthcare, LLC
Not applicable
2,400
Birmingham, Leicester, Edinburgh, Glasgow, Manchester, Nottingham
2021-04-24
Active, closed
Eli Lilly and Company
Phase 3
101
Bristol, Liverpool, Nottingham, Oxford, Stoke-on-Trent, Sheffield
2021-04-13
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Aberdeen, Plymouth, Newmarket, Glasgow, Nottingham, Oxford, Windsor
2021-04-08
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Bristol, Nottingham, Windsor, London, Oxford, Newmarket, Sutton, Manchester
2021-04-05
Active, closed
Celgene
Phase 3
313
Nottingham, Birmingham, Boston, Oxford
2021-02-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
747
Aberdeen, Bath, Nottingham, Southend, London, Northwood, Taunton, Swansea
2021-02-25
Active, closed
Hoffmann-La Roche
Phase 3
270
Glasgow, Leeds, London, Manchester, Nottingham
2021-02-23
Active, closed
AstraZeneca
Phase 3
1,371
Cambridge, Colchester, Leeds, Nottingham, Surrey
2021-01-28
Active, closed
Genmab
Phase 3
483
Birmingham, London, Norwich, Nottingham, Plymouth, Southampton, Sutton, Truro
2021-01-13
Active, closed
Daiichi Sankyo
Phase 3
1,600
Peterborough, Maidstone, Manchester, Metropolitan Borough of Wirral, Nottingham, Bath, Taunton, Leeds
2020-12-04
Active, closed
Hoffmann-La Roche
Phase 2
303
Harlow, London, Nottingham, Peterborough
2020-11-27
Active, closed
Hoffmann-La Roche
Phase 3
985
Glasgow, London, Nottingham, Swansea
2020-10-26
Active, closed
AbbVie
Phase 3
527
Cambridge, Exeter, Edinburgh, London, Southampton, Stevenage, Glasgow, Nottingham
2020-09-30
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Edinburgh, London, Manchester, Nottingham, Sutton
2020-09-30
Active, closed
Ipsen
Phase 3
161
Newcastle upon Tyne, Belfast, Camberley, Cambridge, Hull, London, Nottingham, Plymouth
2020-09-24
Active, closed
Hoffmann-La Roche
Phase 1/2
237
London, Manchester, Newcastle upon Tyne, Nottingham
2020-08-12
Active, closed
GlaxoSmithKline
Phase 3
242
Basingstoke, Glasgow, London, Newcastle upon Tyne, Nottingham, Plymouth, Reading Berkshire, Southampton
2020-07-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
520
Rhyl, Torquay, Preston, London, Nottingham, Darlington
2020-05-19
Active, closed
GlaxoSmithKline
Phase 3
325
Airdrie, Dundee, Edinburgh, London, Nottingham, Oxford, Plymouth, Stoke-on-Trent
2020-04-02
Active, closed
Eli Lilly and Company
Phase 3
261
Nottingham
2020-02-17
Active, closed
RhoVac APS
Phase 2
180
Liverpool, London, Nottingham, Southampton
2019-11-19
Recruiting
GlaxoSmithKline
Phase 1/2
184
Birmingham, Cardiff, Glasgow Strathclyde, London, Manchester, Nottingham, Southampton
2019-10-25
Active, closed
Novo Nordisk A/S
Phase 3
134
Birmingham, London, Manchester, Nottingham, Sheffield
2019-10-21
Active, closed
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
NCT04079166Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
DrugsDNA vaccine·ImmunoBody
Scancell Ltd
Phase 2
173
Cambridge, Cardiff, Leeds, London, Manchester, Northwood, Nottingham, Oxford
2019-08-19
Active, closed
Hoffmann-La Roche
Phase 3
1,013
Cardiff, Glasgow, Inverness, London, London, GT LON, Nottingham, Plymouth, Salford
2019-08-12
Active, closed
Infant Bacterial Therapeutics
Phase 3
2,158
Nottingham
2019-07-04
Active, closed
Novo Nordisk A/S
Phase 3
1,500
Harrogate, Nottingham, Yeovil, London, Norfolk, Nuneaton, Somerset, Truro
2019-05-08
Recruiting
AstraZeneca
Phase 3
140
Glasgow, Hampshire, Manchester, Nottingham
2019-04-02
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Bristol, Nottingham, Colchester, London, Solihull, Truro
2018-12-27
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Truro, Sutton, Cardiff, London, Nottingham, Oxford, Preston, Stoke-on-Trent
2018-12-07
Active, closed
AstraZeneca
Phase 3
1,063
Edinburgh, London, Metropolitan Borough of Wirral, Nottingham, Sheffield
2018-11-16
Active, closed
AbbVie
Phase 3
265
Cambridge, London, Norwich, Nottingham, Glasgow, Stoke-on-Trent, Manchester, Portsmouth
2018-10-22
Active, closed
AbbVie
Phase 2
270
London, Nottingham, Oxford, Birmingham
2018-10-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Leicester, Metropolitan Borough of Wirral, London, Sutton, Nottingham, Birmingham, Newcastle upon Tyne, Plymouth
2018-04-24
Active, closed
Janssen Research & Development, LLC
Phase 1/2
125
Lancaster, London, Nottingham
2018-04-05
Active, closed
Acerta Pharma BV
Phase 1
12
Birmingham, Bournemouth, Cardiff, Leeds, London, Nottingham, Oxford, Southampton
2018-01-31
Active, closed
Gilead Sciences
Phase 3
340
Birmingham, Hull, London, Newcastle upon Tyne, Nottingham, Plymouth, Portsmouth
2017-12-12
Active, closed
Hoffmann-La Roche
Phase 3
382
London, Manchester, Metropolitan Borough of Wirral, Nottingham, Surrey
2017-09-20
Recruiting
The Campbell Clinic, UK
Observational
300
Nottingham
2017-01
Active, closed
DePuy Orthopaedics
Not applicable
540
Wigan, Nottingham
2016-09-01
Active, closed
Xcovery Holdings, Inc.
Phase 3
290
Blackwood, Bristol, Metropolitan Borough of Wirral, Nottingham
2016-06
Active, closed
UK Infinity, Post-Market Clinical Follow-up Study
NCT03063593Arthritis, Rheumatoid, Post-traumatic Osteoarthritis, Degenerative Arthritis
Stryker Trauma and Extremities
Observational
500
Torquay, Bournemouth, Bothwell, Oswestry, Sheffield, Nottingham, Bristol, Edinburgh
2016-04-29
Active, closed
ReCor Medical, Inc.
Not applicable
282
Bournemouth, London, Basildon, Exeter, Hastings, Nottingham
2016-03
Active, closed
Geron Corporation
Phase 2/3
289
Leeds, Nottingham, Southampton, Aberdeen
2016-01-12
Active, closed
AstraZeneca
Phase 3
953
Guildford, London, Manchester, Metropolitan Borough of Wirral, Nottingham, Taunton, Wolverhampton
2015-11-03
Active, closed
Eli Lilly and Company
Phase 3
545
London, Chelsea, Nottingham
2015-05-06
Active, closed
Acerta Pharma BV
Phase 2
124
Cardiff, Leeds, Leicester, Nottingham, Oxford, Plymouth, Southampton
2015-03-02
Active, closed
AstraZeneca
Phase 3
510
Aberdeen, London, Manchester, Nottingham, Sutton, Wolverhampton
2013-09-25
Active, closed
Bristol-Myers Squibb
Observational
2,555
Truro, Leeds, Liverpool, Nottingham, Stafford, Swansea
2012-06-13
Active, closed
Genentech, Inc.
Phase 2
378
Dundee, Edinburgh, Grimsby, Lancaster, London, Manchester, Middlesex, Nottingham
2008-10-16
Recruiting
Exactech Shoulder Post Market Clinical Follow-up Study
NCT05603728Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy
Exactech
Observational
20,000
Reading, Yeovil, Bath, Bedford, Ipswich, Leicester, Manchester, Nottingham
2007-07-19
Rows per page Showing 1–205 of 205
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-uk/city/nottingham

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 11 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 205 of those studies with a site in Nottingham.

How many clinical trials are recruiting in Nottingham?

89 of the 205 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:15 UTC sync. A further 1 have not yet opened recruitment, 114 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nottingham), 205 studies
PhaseStudiesRecruitingShare
Phase 31254861%
Phase 2281013.7%
Observational1577.3%
Phase 11275.9%
Phase 1/21175.4%
Not applicable1084.9%
Phase 2/3422%

Most active sponsors

Lead sponsors with the most studies (Nottingham)
Lead sponsorStudiesRecruiting
AstraZeneca187
Hoffmann-La Roche152
Merck Sharp & Dohme LLC127
AbbVie113
Eli Lilly and Company62
Janssen Research & Development, LLC62
Novartis Pharmaceuticals62
Daiichi Sankyo52
GlaxoSmithKline52
Incyte Corporation52
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.